OverviewChartNewsTraderScreen

BVT Aktienanleihe AMD 28.06.2024/  DE000VM0M526  /

Frankfurt Zert./VONT
13/05/2024  10:37:34 Chg.-0.080 Bid10:37:34 Ask10:37:34 Underlying Strike price Expiration date Option type
101.280EUR -0.08% 101.280
Bid Size: 50,000		 101.780
Ask Size: 50,000		 Advanced Micro Devic... 108.22 USD 28/06/2024 Call
GlobeNewswire 11:00 AMD Remains the Partner of Choice for World’s Fastest and Most Efficient High Performance Computing ...
GlobeNewswire 09/05 Clearside Biomedical Announces First Quarter 2024 Financial Results and Provides Corporate Update
GlobeNewswire 09/05 Adverum Biotechnologies Reports First Quarter 2024 Financial Results and Provides Pipeline Highlight...
GlobeNewswire 09/05 4DMT Reports First Quarter 2024 Financial Results and Operational Highlights
GlobeNewswire 08/05 Alkeus Pharmaceuticals Announces Positive Interim Results Demonstrating No Signs of Disease Progress...
GlobeNewswire 08/05 Therini Bio Announces Positive Preclinical Data Supporting the Development of THN391 in Neurodegener...
GlobeNewswire 08/05 AMD Receives IEEE 2024 Corporate Innovation Award for Leadership in Chiplet Design for High-Performa...
GlobeNewswire 08/05 Belite Bio to Host Webcast on May 14, 2024, to Discuss First Quarter 2024 Financial Results
GlobeNewswire 08/05 EyePoint Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Corporat...
GlobeNewswire 07/05 Ocular Therapeutix™ Reports First Quarter 2024 Results
GlobeNewswire 07/05 Optiver Chooses AMD Enterprise Portfolio to Power its Data Center Modernization, Enabling New Era of...
GlobeNewswire 07/05 Apellis Pharmaceuticals Reports First Quarter 2024 Financial Results
GlobeNewswire 07/05 Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire 06/05 Important Advances in Oxurion's R&D Program on Geographic Atrophy secondary to AMD
GlobeNewswire 06/05 Belite Bio to Participate in Key Opinion Leader Webinar to Discuss Unmet Needs In Stargardt Disease ...
GlobeNewswire 06/05 Belite Bio Presents Additional Analysis from Phase 2 Study of Tinlarebant in Stargardt Disease at th...
GlobeNewswire 06/05 Ocular Therapeutix™ to Present at Two Upcoming Investor Conferences
GlobeNewswire 06/05 EyePoint Pharmaceuticals Announces Topline Data from the Phase 2 PAVIA Trial of DURAVYU™ in Non-Prol...
GlobeNewswire 03/05 Ocular Therapeutix™ To Present at Two Ophthalmology Meetings, May 4-9, 2024
GlobeNewswire 03/05 YieldMax™ ETFs Announces Monthly Distributions on CONY (109.51%), MSTY (103.22%), NFLY (67.74%), SQY...
GlobeNewswire 02/05 Outlook Therapeutics® to Present at the Retina World Congress 2024
GlobeNewswire 02/05 Kriya Announces Three Presentations at the 2024 Association for Research in Vision and Ophthalmology...
GlobeNewswire 02/05 YieldMax™ Launches Short TSLA Option Income Strategy ETF CRSH
GlobeNewswire 01/05 Belite Bio Announces Presentation at the Association for Research in Vision and Ophthalmology 2024 A...
GlobeNewswire 01/05 Gene Therapies in Degenerative Retinal Disease Hold Potential to Capture Significant Portion of Mark...